Filing summary
Issuer discrepancy: The supplied filing is for Zafgen, Inc., not Larimar Therapeutics, Inc. It is a Form 10-Q for the quarter ended September 30, 2014, filed November 13, 2014. Confirm that this is the intended filing before relying on this summary.
Business context and reporting period
Zafgen was a clinical-stage biopharmaceutical company developing beloranib for obesity and related disorders, including Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity. It had no product revenue. The financial statements are unaudited; amounts below are in U.S. dollars, millions, except per-share data.
Key financial metrics
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $12.076 | $2.444 | $20.046 | $7.038 |
| General and administrative expense | $2.285 | $1.080 | $4.822 | $2.981 |
| Net loss | $(14.689) | $(3.504) | $(25.547) | $(10.181) |
| Net loss per share, basic and diluted | $(0.65) | $(4.88) | $(2.97) | $(14.19) |
| Operating cash used | Not stated for quarter | Not stated for quarter | $(16.527) | $(10.871) |
Margins are not meaningful because the company had no revenue. At September 30, 2014, cash and cash equivalents were $127.030, total current assets $129.469, total current liabilities $11.621, total assets $129.636, and total liabilities $18.440. Notes payable were $7.503 carrying value, split between $0.684 current and $6.819 long-term, net of discount. Accumulated deficit was $94.454.
For the first nine months of 2014, financing activities provided $108.139, including $102.672 net IPO proceeds and $7.386 net proceeds from notes; investing activities used $0.099. Cash increased $91.513 from year-end 2013.
Material changes versus prior periods
- Q3 operating expenses rose $10.837 year over year; R&D accounted for $9.632 of the increase. The 2014 quarter included a $6.700 beloranib licensing milestone triggered by initiation of a Phase 3 PWS trial.
- Nine-month R&D expense increased $13.008 year over year, reflecting beloranib development, the milestone, and increased early-stage program and unallocated costs. Nine-month net loss increased $15.366.
- Cash increased substantially following the June 2014 IPO, which sold 6.9 million shares at $16 per share. The IPO also converted all outstanding redeemable convertible preferred stock into common shares.
- The company entered a credit facility in March 2014 and drew $7.5 million. Additional borrowing capacity of up to $12.5 million was not used and expired.
Outlook, risks and unusual items
- Management said September 30 cash was expected to fund operating expenses and capital needs for at least 12 months, while cautioning that assumptions could prove wrong. It expected increasing losses and expenses as clinical development advanced and stated that additional financing would be needed over time.
- The first U.S. Phase 3 PWS trial began in September 2014. Management planned a second PWS Phase 3 trial in Europe around mid-2015, a general-obesity Phase 2b trial in Q4 2014, and continued Phase 2a work in hypothalamic injury-associated obesity. These are plans, not guarantees.
- Beloranib was the company’s principal clinical-stage asset; other candidates, including ZGN-839 and second-generation MetAP2 inhibitors, remained early-stage. Development, regulatory approval, manufacturing, trial enrollment, third-party CRO and supplier performance, intellectual property, and financing were material risks.
- Reported Q3 adverse events in prior Phase 2a trials included sleep disturbances, nausea, and vomiting. The company reported no serious adverse events attributed to beloranib in its trials at that time; later-stage efficacy and safety remained uncertain.
- Accrued expenses included $6.700 of licensing milestones. The company also disclosed up to $19.0 million of future beloranib pre-commercialization milestones, up to $12.5 million of commercialization milestones, and potential royalties if products were commercialized. Debt was secured by substantially all personal property other than intellectual property and included an 8.1% interest rate and a 6% final payment on drawn amounts.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls at quarter-end. It had no revenue and had not established that it would become profitable.
Important facts for investors to verify
- Whether this Zafgen filing, rather than a Larimar Therapeutics filing, is the intended source.
- Clinical-trial progress, results, safety findings, and regulatory requirements for beloranib, including whether stated trial timelines were achieved.
- Cash runway against operating cash use, planned development spending, and any subsequent financing.
- Payment timing and amounts for the accrued $6.7 million milestone, remaining license milestones, and credit-facility obligations.
- Whether the filing’s stated 12-month liquidity expectation and forward-looking development plans remained valid in subsequent disclosures.